Adaptive anoikis resistance promotes ovarian cancer metastasis
RNA-seq (gene expression) · human · 34 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Ovarian cancerThis series is part of our curated briefing on it.
- Samples
- 34 samples: 34 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE241546_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1008671 and SRA study SRP456839. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 34 sample titles: 34 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7730651 OV90_P0A_2D
- GSM7730652 OV90_P0B_2D
- GSM7730653 OV90_P0C_2D
- GSM7730654 OV90_P1A_3D
- GSM7730655 OV90_P1B_3D
- GSM7730656 OV90_P1C_3D
- GSM7730657 OV90_P3A_2D
- GSM7730658 OV90_P3B_2D
- GSM7730659 OV90_P3C_2D
- GSM7730660 OV90_P4A_3D
- GSM7730661 OV90_P4B_3D
- GSM7730662 OV90_P4C_3D
- GSM7730663 OV90_P6A_2D
- GSM7730664 OV90_P6B_2D
- GSM7730665 OV90_P6C_2D
- GSM7730666 OV90_P7A_3D
- GSM7730667 OV90_P7B_3D
- GSM7730668 OV90_P7C_3D
- GSM7730669 OV90_P0A_WES
- GSM7730670 OV90_P0B_WES
- GSM7730671 OV90_P7A_WES
- GSM7730672 OV90_P7B_WES
- GSM7730673 CAOV3_P0A_2D
- GSM7730674 CAOV3_P0B_2D
- GSM7730675 CAOV3_P0C_2D
- GSM7730676 CAOV3_P1A_3D
- GSM7730677 CAOV3_P1B_3D
- GSM7730678 CAOV3_P1C_3D
- GSM7730679 CAOV3_P6A_2D
- GSM7730680 CAOV3_P6B_2D
- GSM7730681 CAOV3_P6C_2D
- GSM7730682 CAOV3_P7A_3D
- GSM7730683 CAOV3_P7B_3D
- GSM7730684 CAOV3_P7C_3D
- GSE107251 Hypoxia-inducible factor-1α promotes cell survival during ammonia stress response in ovarian cancer stem-like cells 15 samples same disease briefing · shares promotes, ovarian
- GSE135242 Hi-C identifies structural variation associated with resistance in paired patient-derived ovarian cancer models 8 samples same disease briefing · shares resistance, ovarian
- GSE268514 Integrative genomic analysis of Korean high-grade serous ovarian cancer 161 samples same disease briefing · shares ovarian
- GSE57477 Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes 72 samples same disease briefing · shares ovarian
- GSE314300 Rb CUT&RUN profiling in ovarian cancer cell lines following CDK2 inhibitor treatment 10 samples same disease briefing · shares ovarian
- GSE311212 Transcriptomic profiling in human ovarian cancer cell line OVCAR-3 following CDK2 inhibitor treatment 6 samples same disease briefing · shares ovarian
- GSE128098 TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target 4 samples same disease briefing · shares ovarian
- GSE154600 Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma 5 samples same disease briefing · shares ovarian
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.